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Hemolysis, oxidative stress, inﬂammation, vaso-occlusion, and organ infarction are
hallmarks of sickle cell disease (SCD). We have previously shown that increases in heme
oxygenase-1 (HO-1) activity detoxify heme and inhibit vaso-occlusion in transgenic mouse
models of SCD. HO-1 releases Fe2+ from heme, and the ferritin heavy chain (FHC)
ferroxidase oxidizes Fe2+ to catalytically inactive Fe3+ inside ferritin. FHC overexpression
has been shown to be cytoprotective. In this study, we hypothesized that overexpression
of FHC and its ferroxidase activity will inhibit inﬂammation and microvascular stasis in
transgenic SCD mice in response to plasma hemoglobin. We utilized a Sleeping Beauty
(SB) transposase plasmid to deliver a human wild-type-ferritin heavy chain (wt-hFHC)
transposable element by hydrodynamic tail vein injections into NY1DD SCD mice. Control
SCD mice were infused with the same volume of lactated Ringer’s solution (LRS) or a
human triple missense FHC (ms-hFHC) plasmid with no ferroxidase activity. 8 weeks
later, LRS-injected mice had ∼40% microvascular stasis (% non-ﬂowing venules) 1 h after
infusion of stroma-free hemoglobin, while mice overexpressing wt-hFHC had only 5%
stasis (p < 0.05), and ms-hFHC mice had 33% stasis suggesting vascular protection by
ferroxidase active wt-hFHC.The wt-hFHC SCD mice had marked increases in splenic hFHC
mRNA and hepatic hFHC protein, ferritin light chain (FLC), 5-aminolevulinic acid synthase
(ALAS), heme content, ferroportin, nuclear factor erythroid 2-related factor 2 (Nrf2), and
HO-1 activity and protein. There was also a decrease in hepatic activated nuclear factor-
kappa B (NF-κB) phospho-p65 and vascular cell adhesionmolecule-1 (VCAM-1). Inhibition of
HO-1 activity with tin protoporphyrin demonstrated HO-1 was not essential for the protec-
tion by wt-hFHC.We conclude that wt-hFHC ferroxidase activity enhances cytoprotective
Nrf2-regulated proteins including HO-1, thereby resulting in decreased NF-κB-activation,
adhesion molecules, and microvascular stasis in transgenic SCD mice.
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INTRODUCTION
Heme-driven oxidative stress and inﬂammation play critical roles
in vaso-occlusion, endothelial cell dysfunction and chronic vas-
culopathy in SCD (Kato et al., 2007, 2009; Belcher et al., 2010a;
Hebbel, 2011; Ghosh et al., 2013). Sickle red blood cells hemolyze,
releasing hemoglobin into the vasculature, which, when oxi-
dized to methemoglobin, can release toxic heme that promotes
oxidative stress and inﬂammation (Jia et al., 2007; Mollan and
Alayash, 2013; Schaer et al., 2013; Belcher et al., 2014). Normally,
plasma hemoglobin and heme are removed safely by haptoglobin
and hemopexin, but these cytoprotective scavenging proteins are
depleted in the plasmaof SCDpatients andmice (Muller-Eberhard
et al., 1968;Wochner et al., 1974; Mollan andAlayash, 2013;Vinchi
et al., 2013; Belcher et al., 2014).
Transgenic sickle mice have vascular inﬂammation which is
critical for blood cell adhesion and vaso-occlusion (Belcher et al.,
2003; Kaul et al., 2004; Zhang et al., 2013). We have recently shown
that free heme can activate endothelium in vivo and in vitro via
the toll-like receptor 4 (TLR-4) causing Weibel-Palade body exo-
cytosis with expression of P-selectin and von Willebrand factor on
their surfaces and activation of the pro-inﬂammatory transcrip-
tion factorNF-κB (Belcher et al., 2014). Supplemental haptoglobin
or hemopexin can prevent endothelial activation and Hb/heme-
induced vaso-occlusion (Schaer et al., 2013; Belcher et al., 2014).
Detoxiﬁcation of heme requires HO, either the inducible HO-1 or
the constitutive HO-2 (Otterbein et al., 2003; Maines and Gibbs,
2005). We have shown that although HO-1 is increased in sickle
patients and mice, pharmacologic or gene therapy augmentation
of HO-1 activity provides protection against inﬂammation and
vaso-occlusion in sickle mice (Nath et al., 2001; Jison et al., 2004;
Belcher et al., 2006, 2010b). HO-1 degrades heme releasing Fe2+,
carbon monoxide, and biliverdin/bilirubin. We and others have
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shown that CO, either inhaled or delivered by hemoglobin as
MP4CO, has salutary effects in sickle mice and in human endothe-
lial cells in vitro (Beutler, 1975; Belcher et al., 2006, 2013; Beckman
et al., 2009). Biliverdin/bilirubin has marked antioxidant and anti-
inﬂammatory effects, both of which are observed in SCD (Belcher
et al., 2006; Kapitulnik and Maines, 2009).
Ferritin, an iron storage protein, plays an important role in
iron and heme-catalyzed oxidative damage. Ferritin is composed
of 24 subunits of two types: heavy (H) and light (L; Harrison
and Arosio, 1996). Ferritin heavy chain (FHC) with its ferroxi-
dase activity detoxiﬁes heme and protects cells against heme and
redox-active iron (Levi et al., 1988; Epsztejn et al., 1999; Cozzi
et al., 2000; Arosio and Levi, 2002). Released Fe2+ from heme
is oxidized via FHC ferroxidase activity, and safely stored as the
catalytically inactive Fe3+. For several years, we have considered
ferritin a cytoprotective antioxidant stratagemof the endothelium.
In fact, we originally reported that FHC ferroxidase that takes up
iron can protect endothelial cells against oxidative injury whereas
ferroxidase-null ferritin does not (Balla et al., 1992,2007). Multiple
investigators have shown, in vitro and in vivo, that FHC can protect
cells and organs (Epsztejn et al., 1999; Cozzi et al., 2000; Berberat
et al., 2003; Xie et al., 2005). A recent review couples heme and
iron metabolism via FHC with the pathogenesis of systemic infec-
tions and inﬂammation through control of labile pro-oxidant iron
(Gozzelino and Soares, 2014).
The ratio of ferritin H and L subunits is tissue speciﬁc and
affects iron storage and availability; this differential expression
may inﬂuence heme-catalyzed oxidative damage (Harrison and
Arosio, 1996). In SCD, iron overload due to enhanced iron
absorption, hemolysis, and red blood cell transfusions leads to
multi-organ dysfunction (Walter et al., 2009; Porter and Gar-
bowski, 2013;Ware and Kwiatkowski, 2013). Serum ferritin, which
primarily reﬂects apo-light chain, is increased in SCD patients
and correlates with total body iron burden. Yet, for unknown
reasons, levels of ferritin are insufﬁcient to handle the catalytic
heme-iron burden in SCD patients. We posited that selectively
increasing FHC ferroxidase activitywould provide a cytoprotective
mechanism in SCD mice. However, effective means of inﬂu-
encing these mechanisms in vivo are lacking. Ferritin-inducing
reagents such as heme and iron, as well as application of recom-
binant FHC, have been shown to protect endothelial cells from
heme-peroxide challenge in cell culture (Balla et al., 1992, 2000;
Lin and Girotti, 1997; Lanceta et al., 2013). Ferritin levels are
controlled by cellular iron levels through a post-translational
interaction with iron-response proteins 1 and 2 (IRP-1 and
IRP-2), releasing these proteins from iron-binding response ele-
ments on ferritin mRNA (Rouault, 2006; Wang and Pantopoulos,
2011). Overexpression of FHC ferroxidase through transfection
of a tetracycline responsive promoter or through an adenovirus
had cytoprotective effects in cultured endothelial, HeLa and
L929 cells; and in rat livers subjected to ischemia/reperfusion
injury (Cozzi et al., 2000; Berberat et al., 2003; Xie et al., 2005).
Since ischemia/reperfusion physiology underpins the pathogen-
esis of SCD, we hypothesized that overexpression of FHC with
ferroxidase activity will attenuate hemoglobin-mediated vaso-
occlusion in mouse models of SCD (Hebbel et al., 2009). We
utilized a novel non-viral delivery system, SB transposase, for
wild type (wt)-FHC and ferroxidase-null missense (ms)-FHC
expression in sickle mice as previously described (Belcher et al.,
2010b).
MATERIALS AND METHODS
CONSTRUCTION OF SLEEPING BEAUTY (SB) TRANSPOSASE/wt-hFHC
AND ms-hFHC
Sticky ended directional cloning of wt human fTH-1 was com-
pleted by use of linker PCR primers. Human sequence gene
speciﬁc PCR primers were designed to include unique restriction
endonuclease sites also found in the pORF5 MCS and six addi-
tional nucleotides 5′ to either the start or stop codons. Total RNA
was puriﬁed from a human umbilical endothelial cell preparation.
Gene speciﬁc reverse transcription was followed by ﬁve cycles of
touch down PCR followed by 37 cycles of PCR using the two
gene speciﬁc primers (Titan one Tube, Roche). PCR product of
∼584 bp was veriﬁed by agarose gel electrophoresis. Ferroxidase-
null 3 ms fTH-1 (E62K, H65G, and K86Q) was created using the
same primers and a PCR target template containing the 3 ms cod-
ing region (kind gift of Dr. Paolo Arosio, Università di Brescia)
and a standard PCR reaction. The 3 ms fTH-1 (ms-hFHC) was
used as a negative control for ferroxidase activity. pORF5-MCS
(InvivoGen) and the PCR products were digested with the match-
ing restriction endonucleases to create direction speciﬁc sticky
ends. The vector and fTH-1 PCR products were cleaned to remove
residual restriction endonucleases, multi cloning site fragment,
and primer tail trim by size exclusion with Qiagen PCR clean
up. The PCR ampliﬁed fTH-1 and pORF-MCS were ligated at
3:1 molar ends ratio overnight using T4 ligase (New England
Biolabs) and then transformed into competent cells. Colonies
present on ampicillin selection bacterial plates were screened for
gain-of-mass and restrictionmappingon agarose gel electrophore-
sis, ligation gap PCR reactions, and DNA was conﬁrmed by
sequencing.
pORF-MCS/human fTH-1 plasmid DNA was digested with
unique restriction endonucleases AsiSi and SwaI (NEB) to release
the, hEF1-eIF4g prom/human fTH-1/SV40pAn cassette from
the plasmid basic elements. The hEF1-eIF4g prom/human fTH-
1/SV40pAn was puriﬁed using agarose gel mass separation and
PCR clean up (Qiagen), and then blunted with Klenow reaction. A
blunt opening between the IR/DR sequences of the SB100X plas-
mid was created at the unique restriction endonuclease EcoRV
site. The digested SB100X plasmid was phosphatased to reduce
self religation. Blunt hEF1-eIF4g prom/human fTH-1/SV40pAn
and blunt pKT2/meIF/ SB100X/pAn were ligated at 3:1 molar
ends ratio overnight at 16◦C and transformed into competent
E. coli. Colonies present on kanamycin selection bacterial plates
were screened for gain of mass and DNA was conﬁrmed by Sanger
sequence.
wt−hFHC . . . 61HEEREHAEKLMKLQNQRGGRIFLQDIKKPD
ms−hFHC . . . 61HEKREGAEKLMKLQNQRGGRIFLQDIQKPD
MICE
All animal experiments were approved by the University of Min-
nesota’s Institutional Animal Care and Use Committee. NY1DD
mice were chosen as our sickle mouse model (Fabry et al., 1992).
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Equal numbers of males and females were obtained and were
infused as described below at ages 8–17 weeks. The mice were
housed in speciﬁc pathogen-free housing to minimize com-
mon infectious sources of inﬂammation and fed standard chow
diet.
GENE TRANSFER INTO MICE
DNA (25 μg) was diluted into 0.1 ml LRS/g body weight of recip-
ient mouse, with a maximum of 2.5 ml. DNA given was either
the SB-wt-fTH-1 or the SB-ms-fTH-1 DNA plasmid as described
above. Vehicle control mice were injected with LRS alone. Mice
were anesthetized andDNAwas injected via tail veins over a course
of 5–6 s. Further experiments were conducted 8 weeks after infu-
sion to allow stable expression of resultant proteins (Belcher et al.,
2010b).
MEASUREMENT OF VASCULAR STASIS
Dorsal skin fold chambers were placed as described previously
(Kalambur et al., 2004; Belcher et al., 2005). Mice recovered for
three days to allow healing. At baseline, mice were anesthetized
and free-ﬂowing vessels within the visible ﬁeld were identiﬁed
via intravital microscopy and mapped. After baseline selection of
ﬂowing venules, mice were infused via tail vein with stroma-free
hemoglobin (8μmol/kg; a gift fromDr. MarkYoung, Sangart Inc.)
to simulate a hemolytic event. The same venules were re-examined
1 and 4 h after hemoglobin infusion. Venules with no observable
blood ﬂow were counted as static. The percentage of static vessels
was calculated by dividing the number of static venules at 1 or 4 h
by the total number of venules examined.
HARVEST OF ANIMAL TISSUES
Blood samples and organs were then harvested 4 h after
hemoglobin infusion as described previously (Belcher et al., 2005).
Mice were asphyxiated in CO2 and blood was collected via termi-
nal cardiac puncture. Organs were removed and processed for
immunohistochemistry, RNA analysis, and homogenate prepa-
ration. Portions for immunohistochemistry were immediately
dropped in phosphate-buffered formalin, while other portions
were wrapped in foil, frozen in liquid nitrogen, and stored
at −85oC.
mRNA ANALYSIS
Total RNA was isolated from frozen spleen sections, and human
FHC and mouse HO-1 mRNAs were quantiﬁed using probe based
quantitative PCR against murine GAPDH as a reference gene
(Roche Applied Sciences Universal Probe Library).
WESTERN BLOT ANALYSIS OF LIVER TISSUE FOR FHC, FLC, HO-1,
Bach-1, Nrf2, NF-κB, VCAM-1, ALAS, AND FERROPORTIN
An equal amount of protein (30 μg) from liver microsomes,
nuclei, or cytosol was loaded into lanes in an SDS buffer and
subjected to electrophoresis on 10 or 15% polyacrylamide gels
(Bio-Rad) as previously described (Belcher et al., 2005, 2013,
2014). The samples were transferred to polyvinylidene ﬂuoride
membranes (Millipore) via electrophoresis. The membranes were
probed with rabbit primary antibodies against human FHC (Ori-
gene, #TA301280), mouse HO-1 (Stressgen, #OSA111), mouse
NF-κB p65 (Cell Signaling #3034) mouse NF-κB phospho-p65
(Cell Signaling, #3031), mouse 5-aminolevulinic acid synthase
(ALAS; GeneTex, #GTX104139), mouse ferroportin (Novus Bio-
logicals, #NBP1-21502), mouse ferritin light chain (FLC; Origene,
#TA307874), mouse VCAM-1 (Abcam, #174279), and mouse
GAPDH (Sigma, #G9495). Sites of binding were visualized via
the appropriate secondary IgG conjugated to horseradish per-
oxidase (Santa Cruz). Final detection of bands was done with
ECFTM substrate (GE Healthcare) and read on a StormTM Reader
(GE Healthcare). Membranes were stripped using Restore Strip-
ping Buffer (Thermo Scientiﬁc) and re-probed as described
above.
HO-1 ACTIVITY IN LIVER MICROSOMES
HO-1 activity was measured as previously described from fresh
liver microsome preparations (Belcher et al., 2010b).
HEME CONTENT OF LIVER MICROSOMES
Heme content was measured via the pyridine hemochromogen
method (Balla et al., 1991). Brieﬂy, liver microsomes were com-
bined with pyridine in microcentrifuge tubes, incubated and then
sodium hydroxide was added to each. Aliquots were pipetted in
quadruplicate into microtiter plates. Fresh sodium hydrosulﬁte
was added to duplicates, and potassium ferricyanide to other
duplicates. The plate was read at 557 and 541 nm, the difference of
the two was calculated for the oxidized and reduced samples, and
the ﬁnal concentration was determined by the difference between
the two, expressed as μmols heme/mg protein.
HEK-293 CELL TRANSFECTION
Human embryonic kidney (HEK-293) cells (ATCC CRL-1573)
were grown in 10% FBS DMEM high glucose (Life Technolo-
gies) with 500 uM sodium pyruvate (Life Technologies), 4 mM
L-Glutamine (Life Technologies), 1.5 g/L sodium bicarbonate
(Sigma) and 1% antibiotic (Life Technologies). For transfection,
cells were seeded overnight on glass chamber slides and transfected
at 70% conﬂuence, 2 h prior to transfection cells were washed
twice with 5% FBS DMEM high glucose (Life Technologies) with
500 μM sodium pyruvate, 4 mM L-Glutamine, 1.5 g sodium
bicarbonate without antibiotic. Cells were transfected with 0.1 μg
of DNA/cm2 with human wt- and ms-fTH-1 in pORF plasmids
using Lipofectamine LTX (Life Technologies) as per the instruc-
tions of the manufacturer. The growth medium was replaced 24 h
post-transfection.
IMMMUNOFLUORESCENCE
In order to investigate the cellular distribution of FHC, HEK-293
cellswere ﬁxedwith 3%paraformaldehyde andpermeabilizedwith
0.5% Triton X-100 48 h after transfection. Slides were incubated
with polyclonal goat anti-FHC (Abcam, #ab80587) and then don-
key cy3 (red)-conjugated anti-goat antibody (Jackson ImmunoRe-
search, #705–165). Slides were stained with DAPI (blue) to
illuminate nuclei. Images were taken with confocal microscopy
using 60× objective and merged with Adobe PhotoshopTM. The
percentage of nuclear FHC was estimated using Photoshop by
counting the number of FHC pixels co-localized with DAPI
(nuclear) divided by the total number of FHC pixels in the
image.
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STATISTICAL ANALYSIS
All analyses were performed using SigmaStat 2.0 (SPSS, Chicago,
IL, USA). Comparison of outcomes for treatment groups was
performed using one-way ANOVA.
RESULTS
Human wt- and ferroxidase-null ms-FHC SB transposase DNA
constructs in LRS were infused hydrodynamically into the tail
veins of NY1DD sickle mice. A single death occurred due to
injection-related bleeding complications. After 8 weeks, studies
were performed as described below.
Wt-hFHC and ms-hFHC mRNAs were transcribed in the
spleens of the sicklemice after 8weeks (Figure 1A).Wt-hFHCpro-
tein was expressed in liver microsomes and cytosol (Figure 1B).
LRS injected animals did not demonstrate presence of human
mRNA or human FHC protein (Figures 1A,B).
Overexpression of FHC in NY1DD sickle mice was tested
for its ability to modulate hemoglobin-induced stasis. 8 weeks
after hydrodynamic infusion of LRS or SB FHC plasmids, dor-
sal skin fold chambers were placed and free-ﬂowing venules were
identiﬁed and mapped. After selection of ﬂowing venules, stroma-
free hemoglobin was infused to induce stasis. 1 and 4 h after
hemoglobin infusion, the same venules were re-examined and the
static venuleswere counted.Vascular stasis inducedbyhemoglobin
was inhibited in the skin of sickle mice overexpressing wt-hFHC
(5.2 and 2.5% at 1 and 4 h, respectively, p < 0.05) but not in LRS-
treated sickle mice (39.8 and 45.3% at 1 and 4 h, respectively),
or in sickle mice expressing ms-hFHC (33 and 27% at 1 and 4 h,
respectively; Figure 2).
We have previously shown that HO-1 is a modulator of inﬂam-
mation and vaso-occlusion in transgenic sickle mice both by
induction of HO-1 with heme as well as by HO-1 gene ther-
apy using a SB transposase (Belcher et al., 2010b). In sickle mice
expressing wt-hFHCorms-FHC, there was a signiﬁcant (p< 0.05)
increase in HO-1 mRNA in the liver (Figure 3A). HO-1 protein
was increased in liver microsomes in mice expressing wt-hFHC,
but not ms-FHC or LRS injected animals (Figure 3B). Further-
more, there was no increase in HO-1 activity in the ms-FHC or
the LRS injected animals, while wt-hFHC signiﬁcantly increased
bilirubin production as a measure of HO-1 activity (Figure 3C;
p < 0.001); that such elevation in bilirubin arose from HO-1
was indicated by the marked reduction in bilirubin production
when the competitive inhibitor of HO activity, tin protopor-
phyrin (SnPP), was administered intraperitoneally (40 μmols/kg)
for 3 days prior to organ harvest.
Since HO-1 activity increased with wt-hFHC gene therapy, it
was important to establish whether HO-1 was responsible for
the inhibition of stasis as previously shown (Belcher et al., 2006,
2010b). Thus, mice injected with wt-hFHC in LRS were given
SnPP intraperitoneally to block HO-1 activity. Treatment of ani-
mals overexpressing wt-hFHC with SnPP to inhibit HO-1 activity
did not reverse wt-hFHC’s ability to inhibit stasis (Figure 3D).
Therefore, wt-hFHC protects against vascular stasis in sickle mice
even when HO-1 activity is blocked.
To explore why HO-1 was induced by wt-hFHC, we exam-
ined whether known modulators of HO-1, such as heme, Bach-1
and Nrf-2, played a role. Heme content of liver microsomes was
FIGURE 1 | Human ferritin heavy chain (FHC) expression is increased in
transgenic sickle mice. NYDD1 sickle mice were injected
hydrodynamically with Sleeping Beauty (SB) transposase vector with either
a wild-type (wt) human fTH-1 gene or a triple missense (ms) fTH-1 gene
devoid of ferroxidase activity. Control NY1DD sickle mice were infused
hydrodynamically with lactated Ringer’s solution (LRS). 8 weeks after
hydrodynamic infusion, the spleens and livers were removed and ﬂash
frozen. (A)Total mRNA (n = 4 mice/treatment group) was isolated from the
spleens and transcription of the human wt- and ms-fTH transgene mRNA
was demonstrated by qRT-PCR, values are expressed as mean + SD of the
ratio of FHC to GAPDH mRNA. (B)Western blots of liver microsomes and
cytosol from treated sickle mice were immunostained for FHC expression.
Note that because the third mutation at residue 86 is in a loop section
suspected to be a conformational epitope (Addison et al., 1984), it is likely
that our primary anti-FHC antibody did not bind our triple ms-hFHC protein
on western blots.
signiﬁcantly increased in wt-hFHC mice compared to ms-FHC or
LRS mice (p < 0.05; Figure 4A). Surprisingly, nuclear Bach-1 and
Nrf-2 that the regulate HO-1 expression negatively and positively,
respectively (Sun et al., 2004; Liu et al., 2013), were both increased
in the nuclei of wt-hFHC expressing mice compared to LRS- or
ms-hFHC-treated mice (Figures 4B,C).
To determine the basis for the protective effects of wt-hFHC
on hemoglobin-induced stasis in SCD, we considered the involve-
ment of NF-κB-mediated adhesion molecule expression. We have
previously shown that NF-κB activation plays a critical role in
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FIGURE 2 | wt-hFHC inhibits hemoglobin-induced stasis in NY1DD
sickle mice. Microvascular stasis was measured in a dorsal skin-fold
chamber model 8 weeks after hydrodynamic infusion of LRS, ms-hFHC, or
wt-hFHC SB vectors. Microvascular stasis was measured 1 and 4 h after
infusion of stroma-free hemoglobin (8 μmol/kg) via the tail vein (n = 8 per
group). Values are mean % stasis ± SD, *p < 0.05 for wt-FHC group vs.
both other groups, as calculated by one-way ANOVA.
vascular inﬂammation, endothelial cell adhesion molecule expres-
sion and blood cell adhesion in sickle mice. In an NF-κB p50
knockout bred into sickle NY1DD mice, hemin did not induce
stasis, compared to wt sickle mice (Kollander et al., 2010). Ani-
mals that received gene therapy with wt-hFHC had diminished
hepatic NF-κB activation as evidenced by signiﬁcantly (conﬁrmed
by densitometry, data not shown) decreased phosphorylation of
NF-κB p65 in the nucleus compared to ms-FHC or LRS injected
animals (Figure 5). Similarly, VCAM-1 is an NF-κB-driven adhe-
sion molecule that is required for vaso-occlusion in SCD mice
and was decreased in liver microsomes of animals overexpress-
ing wt-hFHC compared to animals treated with ms-hFHC or LRS
(Figure 5).
Ferritin has been implicated as a nuclear transcription fac-
tor for a variety of genes (Cai et al., 1998; Pountney et al.,
1999; Alkhateeb and Connor, 2010) and could potentially affect
NF-κB activation. Thus, we examined nuclear FHC localization
by immunoﬂuorescence in HEK-293 cells transfected with wt- or
ms-hFHC. There were marked increases in hFHC expression in
cells transfected with wt- and ms-hFHC compared to untreated
cells (Figure 6A). In untreated cells ∼68% of the FHC was co-
localized with the nuclear DAPI stain. Nuclear hFHC expression
was 90 and 96% in cells transfected with wt-hFHC and ms-hFHC,
respectively. In SCD mice, liver nuclear extracts demonstrated
signiﬁcantly increased nuclear hFHC protein on western blot
in mice overexpressing wt-hFHC relative to mice treated with
ms-hFHCor LRS (Figure 6B). The difference inms-hFHC expres-
sion seen by immunoﬂuorescence (Figure 6A, non-denatured
protein) and western blot (Figure 6B, denatured protein) may
be due to differences in antibody preparations used and antibody
recognition of triple ms-hFHC and wt-hFHC under denaturing
and non-denaturing conditions.
We examined whether other proteins involved in iron or heme
metabolism were affected by increases in wt-hFHC. Ferroportin,
ALAS and FLC were markedly increased in the livers of SCD
mice overexpressing wt-hFHC compared to mice treated with ms-
hFHC or LRS (Figures 7A–C). All three iron-related proteins were
markedly increased in mice treated with wt-hFHC compared to
mice treated with ms-hFHC or LRS.
DISCUSSION
Our results indicate that overexpression of wt-hFHC decreases
NF-κBactivation andVCAM-1expression, increasesHO-1 expres-
sion, and attenuates hemoglobin-mediated vaso-occlusion in SCD
mice. Furthermore, the ferroxidase activity of FHC was essential
to this protection, as ms-hFHC did not protect.
We and others have previously shown that anti-inﬂammatory
therapies or treatment with antibodies targeting adhesion
molecules, including VCAM-1, E-selectin, ICAM-1, P-selectin,
α4β1, αVβ3, vWF, or PECAM-1, inhibit vaso-occlusion in
SCD mice (Kaul et al., 2004; Belcher et al., 2005, 2006, 2010b,
2013, 2014). Therefore, it is not surprising that decreases
in inﬂammatory tone as reﬂected by lower NF-κB activa-
tion and VCAM-1 expression in SCD mice overexpressing
wt-hFHC were accompanied by declines in vascular stasis. How-
ever, the mechanism of FHC anti-inﬂammatory action remains
speculative.
Hemoglobin S is known to auto-oxidize 1.7-fold faster than
hemoglobin A resulting in a higher rate of conversion to methe-
moglobin and generation of superoxide (·O2−) radicals and subse-
quent ampliﬁcation of oxidative stress (Hebbel et al., 1988). To that
end, scavenging free hemoglobin and heme with haptoglobin and
hemopexin, two plasma proteins depleted in hemolyzing sickle
cell patients, is a critical defense for the vasculature in SCD.
We and others have shown the beneﬁcial effects of supplemen-
tal haptoglobin or hemopexin in states of free hemoglobin or
free heme excess (Schaer et al., 2013). Detoxifying heme through
the induction of HO-1 is another stratagem that can provide
vasculoprotection in SCD (Belcher et al., 2006, 2010b).
A clear protective beneﬁt has been shown with upregulation,
either pharmacologically or by gene therapy, of the HO-1 system
inmurinemodels of SCD. In SCDpatients, individualswith a short
GT nucleotide repeat in the hmox-1 gene promoter, hence greater
levels of inducible HO-1 protein, had fewer hospitalizations for
acute chest syndrome (Bean et al., 2013). Furthermore, the prod-
ucts of HO-1 including carbon monoxide and biliverdin decrease
vaso-occlusion in sickle mice (Belcher et al., 2006). Iron is released
from heme by HO-1 and ultimately placed as Fe3+ in the core of
ferritin which can safely store ∼4500 atoms of iron. Ferritin’s role
in SCD is usually considered malevolent as elevated serum ferritin
reﬂects iron overload. Ferritin’s potential cytoprotective role in
SCD has not been explored.
The basis for the present study on ferritin in SCD was ini-
tially published in 1992 (Balla et al., 1992). We had shown that
heme, markedly aggravated endothelial cytotoxicity engendered
by oxidants. In contrast, however, if cultured endothelial cells
were brieﬂy pulsed with heme and then allowed to incubate for
a prolonged period (16 h), the cells became highly resistant to
oxidant-mediated injury and to the accumulation of endothelial
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FIGURE 3 | Heme oxygenase-1 (HO-1) is up-regulated in NY1DD sickle
mice expressing human wt-FHC. (A) 8 weeks after hydrodynamic
infusions, liver HO-1, and GAPDH mRNA ratios were measured by
qRT-PCR (n = 4 mice per treatment group). Values are means ± SD,
†p < 0.05 for wt-FHC and ms-FHC vs. LRS, as calculated by one-way
ANOVA. (B) Microsomal membranes (n = 4 mice per treatment group)
were isolated from the livers, run on a western blot (30 μg of
microsomal protein per lane), and immunostained for HO-1 and GAPDH
protein expression. (C) Heme oxygenase (HO) enzymatic activity was
measured by measuring bilirubin production using 2 mg protein of liver
microsomes per reaction (n = 4 mice per treatment group). HO activity in
mice expressing human wt-FHC treated with the HO inhibitor, tin
protoporphyrin (SnPP; 40 μmol/kg/day × 3 days, intraperitoneally), was
also measured. Values are means ± SD, *p < 0.01 for wt-FHC vs. LRS,
ms-FHC, and wt-FHC + SnPP, as calculated by one-way ANOVA.
(D) Microvascular stasis was measured 1 and 4 h after infusion of
stroma-free hemoglobin (8 μmol/kg) via the tail vein in mice treated with
LRS, ms- and wt-FHC (n = 4 mice per group) as seen in Figure 2.
Inhibition of HO activity with SnPP (40 μmol/kg/day × 3 days,
intraperitoneally) did not block the inhibitory effect of wt-FHC on stasis.
Values are mean % stasis ± SD, p < 0.05 for wt-FHC mice vs. LRS and
ms-FHC, as calculated by one-way ANOVA.
lipid peroxidation products. This protection was associated with
the induction for bothHO-1 and ferritin. Differential induction of
these proteins suggested that ferritin was the primary cytoprotec-
tant. A site-directed mutant of ferritin (heavy chain Glu62---Lys;
His65----Gly), which lacks ferroxidase activity and is deﬁcient in
iron sequestering capacity, was completely ineffective in protecting
cells from injury.
In these studies, FHC was designed to integrate ubiquitously
using an SB100X transposase driven by a constitutive hEF1-eIF4g
promoter. The transposase, delivered in cis with the wt- and ms-
fTH-1 transgene, binds to IR/DR sites ﬂanking the transgene,
and catalyzes the excision of the ﬂanked transgene, mediating its
insertion into the target host genome with an apparently equal
preference for AT-rich dinucleotide insertion sites in introns,
exons, and intergenic sequences (Vigdal et al., 2002). We looked
primarily at the liver and spleen in these animals but did not
attempt to identify and characterize speciﬁc integration sites. Tran-
sient (∼4–6 weeks) episomal expression of the transgene can also
occur in organs.
As can be seen in Figure 1, the spleen and liver showed
evidence for integration of the hFHC genes eight weeks after
infusion, with increased levels of mRNA in the spleen and expres-
sion of wt-hFHC protein observed in the liver. Most notably,
sickle animals expressing wt-hFHC were resistant to hemoglobin-
induced stasis (Figure 2), whilems-hFHC- or LRS-treated animals
had signiﬁcant vaso-occlusion.
In this study, HO-1 was up-regulated at both the transcrip-
tional and translational levels in mice treated with wt-hFHC. This
co-expression of FHC and HO-1 suggests intertwined physiology
in cytoprotection rather than independent pathways. However,
in the study published by Balla et al. (1992), inhibition of HO-
1 with SnPP in endothelial cells overexpressing wt-FHC did not
reverse the protection afforded by ferritin. A residual effect of
endogenous CO produced by HO-1 has not been ruled out.
CO has been shown to modulate TLR4 responses in acute pan-
creatitis (Xue and Habtezion, 2014) and possibly responses to
heme in sickle mice. Overexpression of HO-1 or administra-
tion of exogenous CO decreases inﬂammatory tone assessed by
NF-κB activation. The decrease in NF-κB activation in wt-hFHC
mice (Figure 5) could in part be related to increased HO-1
or through anti-oxidative effects of the ferroxidase activity of
wt-hFHC.
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FIGURE 4 | Liver heme content and nuclear Nrf-2 and Bach-1 levels are
elevated in sickle mice expressing human wt-FHC. (A)The heme
content of liver microsomes from sickle mice treated with wt-FHC, ms- or
LRS was determined by the pyridine hemochromogen method
(n = 4).Values are means ± SD, *p < 0.05 by one-way ANOVA for wt-FHC
vs. other groups. Nuclear extracts were isolated from livers, and 30 μg of
nuclear extract protein from each liver was run on a western blot and
immunostained for Bach-1 (B) and Nrf-2 (C). The GAPDH loading control at
the bottom applies to both (B) and (C).
Our initial studies demonstrating the cytoprotective properties
of HO-1 emphasized the attendant induction of ferritin as a neces-
sary accompaniment for HO-1 to confer its protection (Nath et al.,
1992). Our prior studies demonstrating the protective effects of
ferritin in the heme-exposed endothelium revealed that ferritin
can elicit cytoprotection without the concomitant need for intact
HO activity (Balla et al., 1992). Our present studies thus com-
plete the loop by demonstrating that ferritin itself feeds back to
induce HO-1, but such induction of HO-1 is not essential for
ferritin to evince its protective effects. This latter ﬁnding is ger-
mane to recent observations in a mutant murine model in which
H-ferritin is conditionally deleted in the renal proximal tubule;
such mice are markedly sensitive to acute kidney injury, despite
exhibiting higher expression of HO-1 in the kidney (Zarjou et al.,
2013). Thus induced HO-1 may not prove protective if ferritin is
absent, and ferritin can exert protection even in the absence of
functional HO activity.
FIGURE 5 | Decrease in nuclear phospho- and total NF-κB p65 and
VCAM-1 in sickle mice overexpressing wt-FHC. (A) Nuclear extracts
were isolated from livers, and 30 μg of nuclear extract protein from each
liver was run on a western blot and immunostained for phospho- and total
NF-κB p65 in wt-, ms-, and LRS-treated mice (n = 4). (B) Microsomal
membranes were isolated from livers, and 30 μg of microsomal protein
from each liver was run on a western blot and immunostained for VCAM-1.
FIGURE 6 | Human FHC is expressed in the nuclei of mice expressing
wt- and ms-FHC. (A) Immunoﬂuorescence for human FHC (red) in
HEK-293 cells untreated or transfected with wt-FHC or ms-FHC constructs.
Nuclei were stained with DAPI (blue). (B) Nuclear extracts from the livers of
LRS-, ms-, and wt-FHC treated mice (n = 4) were isolated; 30 μg of nuclear
extract protein from each liver was run on western blot and immunostained
for human FHC. Note: different primary antibodies to FHC were used for
(A) and (B).
Bach-1 was increased in liver nuclear extracts from mice over-
expressing wt-hFCH (Figure 4B) despite the marked increases
in HO-1 (Figures 3A–C). Bach-1 and small Maf heterodimers
that bind to Maf recognition elements (MARE) repress HO-1
transcription. Heme binds to Bach-1 and displaces Bach-1/Maf
heterodimers from MARE allowing Nrf2 and other transcription
factors to bind and induce HO-1 transcription. The displaced
Bach-1 is normally exported from the nucleus and degraded. The
elevated nuclear Bach-1 levels, in the face of marked increases
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FIGURE 7 | Mouse ferroportin, 5-aminolevulinic acid synthase
(ALAS), and ferritin light chain (FLC) proteins are increased in sickle
mice overexpressing human wt-FHC. Proteins of subcellular fractions
isolated from livers of wt-, ms-, and LRS-treated mice (n = 4) were run on a
western blot (30 ug protein/lane) and immunostained for (A) microsomal
ferroportin, (B) mitochondrial ALAS, and (C) cytosolic FLC.
in Nrf2 and HO-1, could possibly be related to intracellu-
lar transport or new production of heme. Along with heme
(Figure 4A), ALAS, the rate-limiting enzyme in heme biosynthe-
sis was increased in mice overexpressing wt-hFHC (Figure 7B). It
is possible the wt-hFHC mice increased heme biosynthesis with
altered trafﬁcking of heme/iron in the cell. In animals treated
with wt-FHC, signiﬁcantly higher heme loads and Nrf2 could
potentially overwhelm Bach-1 leading to induction of other cyto-
protectivemolecules. Alternatively, nuclear FHC could prevent the
phosphorylation of Bach-1. Antioxidant-induced phosphoryla-
tion of tyrosine 486 on Bach-1 is essential for the nuclear export of
Bach-1. Perhaps formation of heme/Bach-1 complexes, evenwith-
out nuclear export and degradation, may be sufﬁcient to inhibit
the formation of Bach-1/small Maf heterodimers and binding
to MARE.
Direct nuclear effects of FHC have been described (Pountney
et al., 1999; Surguladze et al., 2004; Alkhateeb and Connor, 2010).
FHC was protective of DNA from UV damage in the corneal
lens cells (Cai et al., 1998). A DNA-binding motif in H-ferritin
raised the novel possibility of a role for ferritin as a conven-
tional transcription factor associated with the beta-globin locus
promoter (Broyles et al., 2001; Alkhateeb and Connor, 2010).
We found wt-hFHC in the nuclei of HEK-293 transfected cells
and in nuclear extracts of liver cells in vivo (Figures 6A,B).
The effect of FHC in the nucleus appears to be speciﬁc to the
heavy chain, in part because the light chain is undetectable
(Alkhateeb and Connor, 2010). We found increased expression of
stress-responsive proteins Nrf-2 and HO-1 in mice overexpress-
ing wt-hFHC raising the question whether nuclear ferritin may
play a role in driving an anti-inﬂammatory cassette of genes. We
found increased ferroportin which could drive iron out of cells,
light chain ferritin to store iron and ALAS to utilize iron in the
mitochondria, ﬁndings that are all in support of this possibility
(Figure 7). As elegantly recently proposed, FHC can have remark-
able effects in a variety of inﬂammatory states due to its ability to
metabolically adapt tissues to ironoverload (Gozzelino and Soares,
2014).
In conclusion, our results support the notion that overexpres-
sion of FHC ferroxidase protects sicklemice from injury associated
with heme-mediated vaso-occlusive disease. Although ferritin has
been posited as cytoprotective for decades, upregulation of FHC
has proven a challenge especially in sickle patients. As with HO-1,
clearly ferritin is more friend than foe in hemolytic disease. Newer
therapeutics, including gene therapy approaches may prove to be
a valuable asset to the management of SCD.
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